Literature DB >> 35175782

SPARC, a Novel Regulator of Vascular Cell Function in Pulmonary Hypertension.

Christine Veith1, Ipek Vartürk-Özcan1, Magdalena Wujak1,2, Stefan Hadzic1, Cheng-Yu Wu1, Fenja Knoepp1, Simone Kraut1, Aleksandar Petrovic1, Marija Gredic1, Oleg Pak1, Monika Brosien1, Marie Heimbrodt1, Jochen Wilhelm1,3, Friederike C Weisel1, Kathrin Malkmus1, Katharina Schäfer1, Henning Gall1, Khodr Tello1, Djuro Kosanovic4, Akylbek Sydykov5, Akpay Sarybaev1, Andreas Günther1, Ralf P Brandes6, Werner Seeger1,3, Friedrich Grimminger1, Hossein A Ghofrani1, Ralph T Schermuly1, Grazyna Kwapiszewska3,7, Natascha Sommer1, Norbert Weissmann1.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) is a life-threatening disease, characterized by excessive pulmonary vascular remodeling, leading to elevated pulmonary arterial pressure and right heart hypertrophy. PH can be caused by chronic hypoxia, leading to hyper-proliferation of pulmonary arterial smooth muscle cells (PASMCs) and apoptosis-resistant pulmonary microvascular endothelial cells (PMVECs). On reexposure to normoxia, chronic hypoxia-induced PH in mice is reversible. In this study, the authors aim to identify novel candidate genes involved in pulmonary vascular remodeling specifically in the pulmonary vasculature.
METHODS: After microarray analysis, the authors assessed the role of SPARC (secreted protein acidic and rich in cysteine) in PH using lung tissue from idiopathic pulmonary arterial hypertension (IPAH) patients, as well as from chronically hypoxic mice. In vitro studies were conducted in primary human PASMCs and PMVECs. In vivo function of SPARC was proven in chronic hypoxia-induced PH in mice by using an adeno-associated virus-mediated Sparc knockdown approach.
RESULTS: C57BL/6J mice were exposed to normoxia, chronic hypoxia, or chronic hypoxia with subsequent reexposure to normoxia for different time points. Microarray analysis of the pulmonary vascular compartment after laser microdissection identified Sparc as one of the genes downregulated at all reoxygenation time points investigated. Intriguingly, SPARC was vice versa upregulated in lungs during development of hypoxia-induced PH in mice as well as in IPAH, although SPARC plasma levels were not elevated in PH. TGF-β1 (transforming growth factor β1) or HIF2A (hypoxia-inducible factor 2A) signaling pathways induced SPARC expression in human PASMCs. In loss of function studies, SPARC silencing enhanced apoptosis and reduced proliferation. In gain of function studies, elevated SPARC levels induced PASMCs, but not PMVECs, proliferation. Coculture and conditioned medium experiments revealed that PMVECs-secreted SPARC acts as a paracrine factor triggering PASMCs proliferation. Contrary to the authors' expectations, in vivo congenital Sparc knockout mice were not protected from hypoxia-induced PH, most probably because of counter-regulatory proproliferative signaling. However, adeno-associated virus-mediated Sparc knockdown in adult mice significantly improved hemodynamic and cardiac function in PH mice.
CONCLUSIONS: This study provides evidence for the involvement of SPARC in the pathogenesis of human PH and chronic hypoxia-induced PH in mice, most likely by affecting vascular cell function.

Entities:  

Keywords:  apoptosis; endothelial cells; hypertension, pulmonary; hypoxia; myocytes, smooth muscle

Mesh:

Substances:

Year:  2022        PMID: 35175782     DOI: 10.1161/CIRCULATIONAHA.121.057001

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  2 in total

Review 1.  The role of SPARC (secreted protein acidic and rich in cysteine) in the pathogenesis of obesity, type 2 diabetes, and non-alcoholic fatty liver disease.

Authors:  Catalina Atorrasagasti; Agostina M Onorato; Guillermo Mazzolini
Journal:  J Physiol Biochem       Date:  2022-08-26       Impact factor: 5.080

2.  Prognostic significance of SPARC expression in non-small cell lung cancer: A meta-analysis and bioinformatics analysis.

Authors:  Guan-Ying Ma; Shuai Shi; Yu-Rui Zhang; Zhi-Bin Guo; Wen-Wu Bai; Zhi-Gang Zhang
Journal:  Oncol Lett       Date:  2022-09-27       Impact factor: 3.111

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.